Bristol-Myers says shareholders vote to approve Celgene takeover


FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo

NEW YORK (Reuters) – Bristol-Myers Squibb Inc’s shareholders voted to approve the drugmaker’s $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

The company said investors holding around 75 percent of its shares had voted in favor of the deal in a preliminary count.

The company also said during a shareholders meeting that it does not expect changes to the company’s dividend policy after the acquisition.

Reporting by Michael Erman, writing by Caroline Humer; Editing by Chizu Nomiyama

Articles You May Like

One dead in Canada’s Quebec as spring floods force evacuations
Tesla investigates video of parked Model S exploding in Shanghai
MLB roundup: Yankees win game, lose Judge to injury
MLB roundup: Rodriguez guides Red Sox past Tigers
Superheroes and a king may set movie records for Disney this summer

Leave a Reply

Your email address will not be published. Required fields are marked *